<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02448966</url>
  </required_header>
  <id_info>
    <org_study_id>NKTRDP-2015BAI12B08-02</org_study_id>
    <nct_id>NCT02448966</nct_id>
  </id_info>
  <brief_title>Traditional Three-incision Esophagectomy Versus Minimally Invasive Thorascopic and Laparoscopic Esophagectomy</brief_title>
  <official_title>Traditional Three-incision Esophagectomy Versus Minimally Invasive Thorascopic/Laparoscopic Esophagectomy for cT1b-3N0-1M0 Thoracic Esophageal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hebei Medical University Fourth Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sichuan Cancer Hospital and Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fujian Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Liaoning Tumor Hospital &amp; Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hunan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tang-Du Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Chest Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Esophageal carcinoma is an aggressive malignancy with poor prognosis. Surgical resection
      remains the most effective method for this malignant disease. VATS esophagectomy has become
      more and more popular in China and around the world. Although VATS esophagectomy has been
      proven to be effective in preventing respiratory complications, there is still no ample
      evidences to demonstrate that VATS esophagectomy is as effective as traditional
      three-incision esophagectomy in lymph node dissection and is equal or superior in long-term
      survival. The purpose of this large scale prospective observational study is to compare the
      minimally invasive thorascopic/laparoscopic esophagectomy with traditional three-incision
      esophagectomy in lymph node dissection, postoperative recovery, postoperative complications,
      and long-term survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Esophageal carcinoma is an aggressive malignancy with poor prognosis,For these patients,
      radical esophagectomy is the cornerstone of multimodality treatment with curative intent.
      Transthoracic esophagectomy is the preferred surgical approach worldwide allowing for en-bloc
      resection of the tumor. However, the percentage of cardiopulmonary complications associated
      with the traditional three-incision esophagectomy is high.Recent studies have shown that the
      minimally invasive thorascopic and laparoscopic esophagectomy is at least equivalent to the
      open transthoracic approach for esophageal cancer in terms of short-term oncological
      outcomes,including reduced blood loss, shorter ICU stay,and lower pulmonary complication
      rate, but the evidence is not ample because the sample size is not enough.The objective of
      this study is to compare the efficacy, perioperative complications, lymph node dissection and
      long term survival between the thoracic esophageal cancer patients treated by minimally
      invasive thorascopic/laparoscopic esophagectomy and open transthoracic esophagectomy by three
      incisions.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Long term survival</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative complications</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>Traditional open esophagectomy</arm_group_label>
    <description>Treated by traditional three-incision esophagectomy in the centers with enough experience in esophagectomy via right thoracotomy and the volume ≧50 cases each year.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Minimally invasive eophagectomy</arm_group_label>
    <description>treated by minimally invasive thorascopic/laparoscopic esophagectomy in the centers with enough experience in VATS esophagectomy and the volume≧50 cases each year.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>open esophagectomy</intervention_name>
    <arm_group_label>Traditional open esophagectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Minimally invasive esophagectomy</intervention_name>
    <arm_group_label>Minimally invasive eophagectomy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        cT1b-3N0-1M0 thoracic esophageal cancer.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with histologically proven squamous cell esophageal cancer, without any
             previous anti-tumor therapy;

          2. Preoperative clinical TNM stage:cT1b-3N0-1M0;

          3. Adequate cardiopulmonary, liver, brain and kidney function which can tolerate the
             esophagectomy either via traditional tree-incision or minimally invasive
             thorascopic/laparoscopic esophagectomy;

          4. Preoperative assessment by CT and EUS is fit for minimally invasive
             thorascopic/laparoscopic esophagectomy;

          5. Willing to participate the clinical trial and sign the informed consent before being
             enrolled into clinical trail.

        Exclusion Criteria:

          1. Previous use of anti-cancer therapy;

          2. Preoperative clinical TNM stage: N2-3 or M1;

          3. Inadequate cardiopulmonary,liver, brain and kidney function for surgery;

          4. Previous malignancy history;

          5. Unwilling to participate the clinical trial and refuse to sign informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jie He, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yousheng Mao, MD</last_name>
    <phone>8610-87787138</phone>
    <email>maoysherx@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhirong Zhang, MD</last_name>
    <phone>8610-87788798</phone>
    <email>zhangzr@cicams.ac.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cancer hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yousheng Mao, MD</last_name>
      <phone>8610-87787138</phone>
      <email>maoysherx@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Zhirong Zhang, MD</last_name>
      <phone>8610-87788798</phone>
      <email>zhangzr@cicams.ac.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Jie He, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2015</study_first_submitted>
  <study_first_submitted_qc>May 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2015</study_first_posted>
  <last_update_submitted>May 19, 2015</last_update_submitted>
  <last_update_submitted_qc>May 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Jie He</investigator_full_name>
    <investigator_title>President</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

